Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4 + T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid
Storage Temp
Protected from light,Store at -80°C
Shipped In
Ice chest + Ice pads
Product Description
Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4 + T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice.
In Vitro
Cirsilineol (0.1-10 μM; 96 hours) inhibits single mixed lymphocyte reaction and Concanava A-induced T-cell proliferation in a dose-dependent manner. Cirsilineol (10 μM) does not affect T lymphocyte's viability. The inhibition of cirsilineol (10 μM) on T-cell proliferation is not due to a cytotoxic activity. Cirsilineol (1-10 μM; pretreatment for 3 hours) completely inhibits IFN-γ-induced Tyr701 phosphorylation of STAT1 and JAK2 activation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Splenocytes Concentration: 0.1, 1, 10 μM Incubation Time: 96 hours Result: Inhibited single mixed lymphocyte reaction and Concanavalin A (Con A; 5 μg/mL; for 72 h)-induced T-cell proliferation in a dose-dependent manner. Suppressed OVA 323-339 -specific CD4 + T-cell proliferation. Western Blot AnalysisCell Line: Splenic CD4 + T cells Concentration: 1, 5, 10 μM Incubation Time: Pretreatment for 3 hours Result: Completely inhibited IFN-γ-induced (25 ng; 30 mins) Tyr701 phosphorylation of STAT1 and JAK2 activation. Suppressed IFN-γ-induced (25 ng; 12 hours) Th1-specific transcription factor T-bet.
In Vivo
cirsilineol (3, 10, and 30 mg/kg) significantly ameliorates TNBS-induced Th1-mediated colitis through inhibiting IFN-γ/STAT1/T-bet signaling in CD4 + T cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 8-10-week-old female C57BL/6, BALB/c and DO11.10 transgenic mice with TNBS (10 mg; 100 μL) Dosage: 3, 10, 30 mg/kg Administration: IP; daily; for 11 days Result: Showed a significant improved effect on the body weights and survival rate of mice. Markedly reduced inflammatory infiltration, restoration of the destructive mucosal architecture and remission of edema.
